Blocking IL6 signaling was shown capable of rewiring the chemotherapeutic resistance of pancreatic cancers in vivo,175 with a clinical trial involving 140 advanced pancreatic cancer patients being launched to examine the efficacy of tocilizumab (an IL6R inhibitor) in improving the chemotherapeutic outcome (NCT02767557). Here, IL6 is linked to familial pancreatic carcinoma.